Skip to main content

Table 3 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in patient subcohorts stratified by treatment (TAM or AI)

From: HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Subgroup Predictor OS DFS
HR 95% CI p value HR 95% CI p value
TAM treated HER4 continuous 1.28 1.01 1.62 0.040 1.16 0.89 1.52 0.270
HER4 expression (ref. no HER4 expression) 1.63 0.52 5.06 0.399 1.23 0.54 2.84 0.622
HER4 ≥ 1 (ref. HER4 < 1) 3.22 1.17 8.86 0.024 1.36 0.63 2.97 0.436
Al treated HER4 continuous 0.86 0.60 1.22 0.393 0.85 0.61 1.18 0.338
HER4 expression (ref. no HER4 expression) 0.68 0.31 1.50 0.339 0.72 0.36 1.44 0.352
  1. Significant values are shows in bold typeface
  2. AI aromatase inhibitor, CI confidence interval, HR hazard ratio, TAM tamoxifen